# US 6,297,225 B1 · Treatment of highly vascular tumors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,297,225 B1
- Document ID: US6297225B1
- Status: Granted
- Kind: B1
- Application number: 09/319,483
- Filed: 1999-09-22
- Granted: 2001-10-02
- Earliest claimed: 1996-12-04
- Assignees: M L Laboratories PLC
- Inventors: Donald Davies; Robert John Edwards; Nigel John Gooderham; Sunil Shaunak
- Web page: https://patentgrep.com/patent/US6297225B1

## CPC

- A61K 31/737: Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate (A61K31/727 takes precedence)
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of treating a patient having a highly vascular tumor includes administering a therapeutically effective amount of dextrin sulphate to the patient. The highly vascular tumor can be, for example, Kaposi's sarcoma. The treatment results in regression of the tumors and the improvement persists for a considerable time after completion of the treatment.

## Claims

### Claim 1

A method of treating a patient having a highly vascular tumour which comprises administering a therapeutically effective amount of dextrin sulphate to the patient.

### Claim 2 (depends on 1)

The method of claim 1 wherein said highly vascular tumour is Kaposi's sarcoma.

### Claim 3 (depends on 1)

The method of claim 1 wherein the dextrin sulphate is administered to the patient intraperitoneally.

### Claim 4 (depends on 1)

The method of claim 1 wherein the dextrin sulphate is derived from a dextrin having at least 50% by weight of glucose polymers of D.P. greater than 12.

### Claim 5 (depends on 1)

The method of claim 1 wherein the dextrin sulphate is derived from a dextrin having more than 90% by weight of glucose polymers of D.P. greater than 12.

### Claim 6 (depends on 1)

The method of claim 1 wherein the dextrin sulphate is derived from a dextrin containing less than 10% by weight of glucose polymers of D.P. less than 12.

### Claim 7 (depends on 1)

The method of claim 1 wherein the dextrin sulphate is derived from a dextrin containing less than 5% by weight of glucose polymers of D.P. less than 12.

### Claim 8 (depends on 1)

The method of claim 1 wherein the dextrin sulphate is derived from a dextrin having a weight average molecular weight of from 10,000 to 35,000.

### Claim 9 (depends on 1)

The method of claim 1 wherein the dextrin sulphate is derived from a dextrin containing less than 10% by weight of glucose polymers of molecular weight greater than 40,000.

### Claim 10 (depends on 1)

The method of claim 1 wherein the dextrin sulphate is derived from a dextrin containing less than 5% by weight of glucose polymers of molecular weight greater than 40,000.

### Claim 11 (depends on 1)

The method of claim 1 wherein the dextrin sulphate contains at most two sulphate groups per glucose unit.

### Claim 12 (depends on 1)

The method of claim 1 wherein the dextrin sulphate contains between 0.5 and 1.5 sulphate groups per glucose unit.

### Claim 13 (depends on 1)

The method of claim 1 wherein the dextrin sulphate is dextrin-2-sulphate or dextrin-6-sulphate or a mixture thereof.

### Claim 14 (depends on 1)

The method of claim 1 wherein the dextrin sulphate is derived from a dextrin having a weight average molecular weight of from 15,000 to 25,000.